The FDA's Most Controversial Director Just Quit. Again.

Then there was uniQure's Huntington's disease gene therapy, AMT-130. Prasad held a briefing demanding additional Phase 3 data, a move significant enough that Rep. Jake Auchincloss flagged him by name in a Congressional inquiry.

For families dealing with devastating genetic conditions, each of these decisions wasn't an abstract regulatory call. It was a door closing on a treatment that might never come back.

The Vaccine Firestorm

Rare diseases weren't the only battlefield.

In November 2025, Prasad dropped an internal memo asserting that COVID vaccines were responsible for the deaths of at least 10 children. He called for requiring full randomized controlled trials (the gold standard of medical evidence, where patients are randomly assigned to get either the real treatment or a placebo) for most vaccines, rather than relying on immune response measurements as a stand-in for effectiveness. This was a radical departure from decades of vaccine regulation.

The pharmaceutical industry pushed back hard. Then came the most dramatic episode of all: in February 2026, Prasad led the FDA in issuing a "refuse-to-file" letter to Moderna for its mRNA flu vaccine candidate, mRNA-1010. In plain English, that means the agency didn't even agree to review the application. One week later, after Moderna submitted an amended version, the decision was reversed.

Imagine applying for a job, being told your resume wouldn't even be read, and then getting an interview seven days later after changing the font. That kind of whiplash doesn't inspire confidence in the process.

A Toxic Workplace, Under Investigation

The controversies went beyond policy disagreements. By late February 2026, Prasad was under formal investigation by the FDA for complaints including retaliation against subordinates and verbally berating staff. The probe, conducted with outside investigator Professional EEO Services, had been running for months.

The damage to CBER's internal culture appears significant. Dozens of scientists reportedly considered leaving the center to escape what was described as an environment "rife with mistrust and paranoia." Staffers were allegedly terrified of pushing back on Prasad for fear of retaliation. He pushed at least seven senior leaders out of their positions without public explanation and reportedly tried to block employees from transferring to other FDA divisions.

Former CDER director George Tidmarsh, who resigned in November 2025, attributed the toxic work environment directly to Prasad. When the person running the show is the reason people are heading for the exits, the show has a problem.

What This Means for Biotech's Hottest Sectors

CBER isn't some sleepy regulatory backwater. It's the gatekeeper for some of the most exciting (and expensive) areas of medicine: CAR-T cancer treatments, CRISPR gene editing, mRNA vaccines, and next-generation biologics.

In 2024, biologics accounted for 16 of the FDA's 50 novel drug approvals, nearly a third. That share is growing. CBER's 2026 guidance agenda includes 19 planned guidances for cell and gene therapy alone, covering everything from potency testing to manufacturing changes to genome-editing products. There are nine more on the docket for vaccines and allergenic products.

With no successor named, all of that work enters a gray zone. Analysts have called the FDA under Prasad "increasingly stringent, and unpredictable." The stringency might ease with his departure, but unpredictability could actually get worse during the transition.

Sen. Bill Cassidy (R-LA) published a HELP Committee white paper characterizing the FDA's review processes as a "black box," noting that companies reported facing a "reviewer lottery" with inconsistent standards. A leadership vacuum at CBER doesn't exactly fix that perception.

The Paradox Nobody's Talking About

Here's what makes Prasad's legacy genuinely complicated: alongside all the rejections and confrontations, CBER under his watch also pushed forward some of the most innovative regulatory frameworks in the agency's history.

The center released draft guidances on expedited programs and innovative clinical trial designs for rare disease therapies. It unveiled a new "bespoke" pathway allowing approval of gene therapies for conditions so rare they might affect only a single patient, based on a "plausible mechanism" rather than traditional large trials. Commissioner Makary and Prasad called it a "revolutionary advance in regulatory science."

Rare disease advocates mostly welcomed these frameworks, even as they clashed with Prasad on individual decisions. Many families see the bespoke pathway as the only realistic route to getting treatments in their lifetimes. The tension is real: the same director who blocked specific therapies also built new roads that could eventually deliver them.

What Happens Now

For biotech companies with products in CBER's pipeline, the practical advice from regulatory watchers boils down to three things.

First, document everything. Treat every FDA meeting as critical. Get specific, written feedback on trial design, endpoints, and manufacturing. Reference those agreements explicitly in future submissions. When leadership changes, institutional memory can be short.

Second, build more evidence than you think you need. Prasad's tenure showed that CBER can demand additional Phase 3 data late in the game. Having surplus evidence is insurance against a regulatory environment that could shift in either direction.

Third, watch the successor closely. Whoever replaces Prasad (and whether they're an acting director or a permanent pick) will send immediate signals about CBER's direction. Advisory committee rosters, mid-year guidance updates, and enforcement priorities will be the earliest tea leaves to read.

The bigger question is whether CBER's career scientists, many of whom reportedly felt sidelined or overruled, will regain influence in the interim. If they do, the center could drift back toward more traditional risk-benefit frameworks. That might mean fewer headline-grabbing confrontations, but it won't automatically mean faster approvals.

Prasad came in as a disruptor. He's leaving behind a center that's been thoroughly disrupted. The question now is whether anyone can put it back together before the pipeline backs up and patients pay the price.